News / Taiwan / economic_daily
TaiMed Biologics Revenue Soars 288% in October on Dual-Engine Strategy
Health Technology · Biotechnology · economic_daily · 2026-11-08
6589
TaiMed Biologics reports a 287.8% year-over-year revenue jump in October, driven by CDMO expansion and international biosimilar licensing milestones.
What Happened
Revenue Surge: TaiMed Biologics saw October revenue exceed NT$270 million, a 287.8% year-over-year increase, with cumulative revenue for the first ten months reaching NT$1.38 billion. Both monthly and cumulative figures hit three-year highs.
Dual-Engine Strategy: Growth is driven by the expansion of the CDMO business and international licensing income from biosimilars. Chairman Liu Li-cheng noted that milestone payments are being recognized according to contract progress, with future revenue expected to include sales royalties following drug approvals.
Regulatory Progress: The biosimilar EG1206A has been submitted to the EMA, with filings in the US and Canada expected by year-end. The company plans to partner with Sandoz to apply for drug approvals in 26 countries by 2027, with peak licensing revenue anticipated between 2027 and 2028.
Future Roadmap: TaiMed is targeting the multiple myeloma market with plans to enter clinical trials for EG12184 in 2027. The company aims to launch a new biosimilar every 12 to 18 months starting in 2029 to expand its global footprint.